ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 16

Novel Serum Broad-Based Proteomic Discovery Analysis Identifies Proteins and Pathways Dysregulated in Juvenile Dermatomyositis (JDM) Myositis Autoantibody Groups

Hanna Kim1, Angélique Biancotto2, Foo Cheung3, Terrance P. O'Hanlon4, Ira N. Targoff5, Yan Huang6, Frederick Miller4, Raphaela Goldbach-Mansky6 and Lisa G. Rider4, 1Pediatric Translational Research Branch, NIAMS/NIH, Bethesda, MD, 2Center for Human Immunology, Autoimmunity and Inflammation (CHI), NHLBI, NIH, Bethesda, MD, 3Center for Human Immunology Autoimmunity and Inflammation (CHI), NHLBI, NIH, Bethesda, MD, 4Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, 5VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, 6Translational Autoinflammatory Disease Studies (TADS), NIAID, NIH, Bethesda, MD

Meeting: Pediatric Rheumatology Symposium 2017

Keywords: autoantibodies, Biomarkers, juvenile dermatomyositis, pathogenesis and proteomics

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Thursday, May 18, 2017

Title: Genetics and Pathogenesis Poster Breakout I

Session Type: Abstract Submissions

Session Time: 4:45PM-5:15PM

Background/Purpose: Juvenile dermatomyositis (JDM) is a complex heterogeneous autoimmune disease.  Myositis-specific autoantibodies (MSAs), present in up to 80% of JDM patients, help define distinct phenotypes within JDM and may indicate distinct pathogeneses.  To define biomarkers and better understand JDM pathogenesis, aptamer-based proteomic technology was used to mine the serum proteome in a well-characterized JDM cohort.

Methods:   Sera from 41 JDM patients (prevalent cases on variable treatment) selected for higher disease activity (physician global activity or PGA median 4.0 (IQR 3.0-5.0)) with anti-p155/140 or TIF1 (n=21), NXP2 (n=10), and MDA5 (n=10) MSAs, were compared with 28 age- and gender-matched healthy controls (HC). Broad proteomic analysis of 1306 targets using SOMAscan assay of slow off-rate modified aptamers (SomaLogic, CO) generated simultaneous quantitative serum levels. Individual MSA group vs. HC proteins with Mann-Whitney FDR-corrected p values of <0.05 with expression ratio of >1.3 were analyzed using Ingenuity Pathway Analysis or IPA (Qiagen, CA). 

Results: 62, 41, and 67 proteins, met above criteria with overexpression (>1.3 ratio versus HC) with 13, 4, and 13 proteins specific to TIF1, NXP2, and MDA5 MSA groups respectively and 26 shared in all 3 groups and 31 shared in 2 groups (Figure 1). Top 10 proteins by MSA group are listed in Table 1. Within the top 20 dysregulated pathways by MSA group by IPA, Th1 and Th2 activation, acute phase response, IFN, and glucocorticoid receptor signaling were shared to all 3 MSA groups.  Further analysis by MSA group is ongoing.

Conclusion: Preliminary broad quantitative proteomic analysis by MSA group compared to HC identified Th1/ Th2, acute phase response, IFN, and glucocorticosteroid receptor signaling shared in all MSA groups. Unique protiens were identified by MSA group, but further analysis by MSA group is pending. While in need of confirmation in other cohorts, these proteins identified through a high-throughput screen bring to light new pathways that may be important in JDM and potential MSA-group specific pathogenesis.

This research was supported by the Cure JM Foundation and the Intramural Research Program of the NIH, NIAMS, NIEHS, NHLBI, NIAID, and the CC. 


Disclosure: H. Kim, 2; A. Biancotto, None; F. Cheung, None; T. P. O'Hanlon, None; I. N. Targoff, 6; Y. Huang, None; F. Miller, None; R. Goldbach-Mansky, None; L. G. Rider, 2.

To cite this abstract in AMA style:

Kim H, Biancotto A, Cheung F, O'Hanlon TP, Targoff IN, Huang Y, Miller F, Goldbach-Mansky R, Rider LG. Novel Serum Broad-Based Proteomic Discovery Analysis Identifies Proteins and Pathways Dysregulated in Juvenile Dermatomyositis (JDM) Myositis Autoantibody Groups [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 4). https://acrabstracts.org/abstract/novel-serum-broad-based-proteomic-discovery-analysis-identifies-proteins-and-pathways-dysregulated-in-juvenile-dermatomyositis-jdm-myositis-autoantibody-groups/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to Pediatric Rheumatology Symposium 2017

ACR Meeting Abstracts - https://acrabstracts.org/abstract/novel-serum-broad-based-proteomic-discovery-analysis-identifies-proteins-and-pathways-dysregulated-in-juvenile-dermatomyositis-jdm-myositis-autoantibody-groups/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology